Triple
T1172237
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Aduhelm |
E24938
|
entity |
| Predicate | clinicalTrial |
P23163
|
FINISHED |
| Object |
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
|
E133123
|
NE FINISHED |
Provenance (6 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69a494082a7c819095004f423f294a64 |
elicitation | completed |
| NER | batch_69a4bceb3f188190b8b767380fe5986f |
ner | completed |
| NED1 | batch_69ac66879aec819098293c440a0e09a6 |
ned_source_triple | completed |
| NED2 | batch_69ac677e147081909d9f64884c443f82 |
ned_description | completed |
| NEDg | batch_69ac66fd58308190bb4cb09581d4a8de |
nedg | completed |
| PD | batch_69a4bb5656948190b0b1d5446ad06005 |
pd | completed |
Created at: March 1, 2026, 7:45 p.m.